Seminars in Oncology
Volume 35, Issue 2 , Pages 147-159 , April 2008

Diagnosis and Treatment of Metastatic Disease to the Liver

  • Cletus A. Arciero
    • ,
  • Elin R. Sigurdson

      Affiliations

    • Corresponding Author InformationAddress correspondence to Elin R. Sigurdson, MD, PhD, Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111.

References 

  1. Braga L, Guller U, Semelka RC. Modern hepatic imaging. Surg Clin North Am. 2004;84:375–400
  2. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224:748–756
  3. Zacherl J, Scheuba C, Imhof M, et al. Current value of intraoperative sonography during surgery for hepatic neoplasms. World J Surg. 2002;26:550–554
  4. Sahani DV, Kalva SP, Tanabe KK, et al. Intraoperative US in patients undergoing surgery for liver neoplasms: comparison with MR imaging. Radiology. 2004;232:810–814
  5. Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—meta-analysis. Radiology. 2005;237:123–131
  6. Ward J, Robinson PJ, Guthrie JA, et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology. 2005;237:170–180
  7. Semelka RC, Cance WG, Marcos HB, Mauro MA. Liver metastases: comparison of current MR techniques and spiral CT during arterial portography for detection in 20 surgically staged cases. Radiology. 1999;213:86–91
  8. Kim HC, Kim TK, Sung KB, et al. CT during hepatic arteriography and portography: an illustrative review. Radiographics. 2002;22:1041–1051
  9. Yu JS, Kim KW, Lee JT, Yoo HS. MR imaging during arterial portography for assessment of hepatocellular carcinoma: comparison with CT during arterial portography. AJR Am J Roentgenol. 1998;170:1501–1506
  10. Sahani DV, Kalva SP, Fischman AJ, et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol. 2005;185:239–246
  11. Desai DC, Zervos EE, Arnold MW, et al. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol. 2003;10:59–64
  12. Rydzewski B, Dehdashti F, Gordon BA, et al. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. AJR Am J Roentgenol. 2002;178:353–358
  13. Wiering B, Krabbe PF, Jager GJ, et al. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005;104:2658–2670
  14. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR Am J Roentgenol. 1997;169:1675–1680
  15. Zealley IA, Skehan SJ, Rawlinson J, et al. Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG PET. Radiographics. 2001;21:S55–S69
  16. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59–71
  17. Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C. Patient selection for hepatic resection of colorectal metastases. Arch Surg. 1996;131:322–329
  18. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver (A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie). Cancer. 1996;77:1254–1262
  19. Jarnagin WR, Conlon K, Bodniewicz J, et al. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer. 2001;91:1121–1128
  20. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–318
  21. Potter MW, Shah SA, McEnaney P, et al. A critical appraisal of laparoscopic staging in hepatobiliary and pancreatic malignancy. Surg Oncol. 2000;9:103–110
  22. Jaffe BM, Donegan WL, Watson F, Spratt JS. Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet. 1968;127:1–11
  23. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver (I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy). Cancer. 1969;23:198–202
  24. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77:1241–1246
  25. Adson MA, van Heerden JA, Adson MH, et al. Resection of hepatic metastases from colorectal cancer. Arch Surg. 1984;119:647–651
  26. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10:663–669
  27. Bismuth H, Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol. 1998;25(Suppl 5):40–46
  28. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509–520
  29. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986;100:278–284
  30. Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505–510
  31. D’Angelica M, Brennan MF, Fortner JG, et al. Ninety-six five-year survivors after liver resection for metastatic colorectal cancer. J Am Coll Surg. 1997;185:554–559
  32. Hughes KS, Rosenstein RB, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases (A multi-institutional study of long-term survivors). Dis Colon Rectum. 1988;31:1–4
  33. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–946
  34. Lise M, Bacchetti S, Da Pian P, et al. Patterns of recurrence after resection of colorectal liver metastases: prediction by models of outcome analysis. World J Surg. 2001;25:638–644
  35. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189:291–299
  36. August DA, Sugarbaker PH, Schneider PD. Lymphatic dissemination of hepatic metastases (Implications for the follow-up and treatment of patients with colorectal cancer). Cancer. 1985;55:1490–1494
  37. Rashidi B, Gamagami R, Sasson A, et al. An orthotopic mouse model of remetastasis of human colon cancer liver metastasis. Clin Cancer Res. 2000;6:2556–2561
  38. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection (Registry of Hepatic Metastases). Surgery. 1988;103:278–288
  39. Headrick JR, Miller DL, Nagorney DM, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg. 2001;71:975–979
  40. Murata S, Moriya Y, Akasu T, et al. Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer. 1998;83:1086–1093
  41. Cady B, Jenkins RL, Steele GD, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg. 1998;227:566–571
  42. Steele G, Bleday R, Mayer RJ, et al. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol. 1991;9:1105–1112
  43. Weber SM, Jarnagin WR, DeMatteo RP, et al. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol. 2000;7:643–650
  44. Jessup JM, McGinnis LS, Steele GD, et al. The National Cancer Data Base (Report on colon cancer). Cancer. 1996;78:918–926
  45. Rosen SA, Buell JF, Yoshida A, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be?. Arch Surg. 2000;135:530–534
  46. Adson MA. Resection of liver metastases—when is it worthwhile?. World J Surg. 1987;11:511–520
  47. Doci R, Gennari L, Bignami P, et al. Morbidity and mortality after hepatic resection of metastases from colorectal cancer. Br J Surg. 1995;82:377–381
  48. Brown DA, Pommier RF, Woltering EA, Fletcher WS. Nonanatomic hepatic resection for secondary hepatic tumors with special reference to hemostatic technique. Arch Surg. 1988;123:1063–1066
  49. Ohrvall U, Eriksson B, Juhlin C, et al. Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg. 2000;24:1402–1408
  50. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37
  51. Chung MH, Pisegna J, Spirt M, et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery. 2001;130:954–962
  52. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg. 2005;241:776–783
  53. Rose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg. 2001;136:950–955
  54. DeMatteo RP, Shah A, Fong Y, et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg. 2001;234:540–547
  55. Elias D, Lasser PH, Montrucolli D, et al. Hepatectomy for liver metastases from breast cancer. Eur J Surg Oncol. 1995;21:510–513
  56. Miyazaki M, Itoh H, Nakagawa K, et al. Hepatic resection of liver metastases from gastric carcinoma. Am J Gastroenterol. 1997;92:490–493
  57. Ambiru S, Miyazaki M, Ito H, et al. Benefits and limits of hepatic resection for gastric metastases. Am J Surg. 2001;181:279–283
  58. Roh HR, Suh KS, Lee HJ, et al. Outcome of hepatic resection for metastatic gastric cancer. Am Surg. 2005;71:95–99
  59. Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg. 1998;187:487–493
  60. Harrison LE, Brennan MF, Newman E, et al. Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery. 1997;121:625–632
  61. Weitz J, Blumgart LH, Fong Y, et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg. 2005;241:269–276
  62. Ercolani G, Grazi GL, Ravaioli M, et al. The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol. 2005;12:459–466
  63. Sullivan RD, Zurek WZ. Chemotherapy for liver cancer by protracted ambulatory infusion. JAMA. 1965;194:481–486
  64. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685–693
  65. Martin JK, O’Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer (A randomized trial). Arch Surg. 1990;125:1022–1027
  66. Ensminger WD, Rosowsky A, Raso V, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2’-deoxyuridine and 5-fluorouracil. Cancer Res. 1978;38:3784–3792
  67. Balch CM, Urist MM, Soong SJ, McGregor M. A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg. 1983;198:567–573
  68. Niederhuber JE, Ensminger W, Gyves J, et al. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer. 1984;53:1336–1343
  69. Weiss GR, Garnick MB, Osteen RT, et al. Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol. 1983;1:337–344
  70. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10:1112–1118
  71. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000;18:243–254
  72. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma (A randomized trial). Ann Intern Med. 1987;107:459–465
  73. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol. 1989;7:1646–1654
  74. Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344:1255–1260
  75. Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol. 1990;8:1885–1893
  76. Grage TB, Vassilopoulos PP, Shingleton WW, et al. Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: a Central Oncology Group study. Surgery. 1979;86:550–555
  77. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet. 2003;361:368–373
  78. Durand-Zaleski I, Roche B, Buyse M, et al. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases (Meta-Analysis Group in Cancer). J Natl Cancer Inst. 1997;89:790–795
  79. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer (Meta-Analysis Group in Cancer). J Natl Cancer Inst. 1996;88:252–258
  80. Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver (Is there a survival difference? Meta-analysis of the published literature). Cancer. 1996;78:1639–1645
  81. Rudroff C, Altendorf-Hoffmann A, Stangl R, Scheele J. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg. 1999;384:243–249
  82. Tono T, Hasuike Y, Ohzato H, et al. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: a randomized study. Cancer. 2000;88:1549–1556
  83. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–2048
  84. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer (German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)). Ann Surg. 1998;228:756–762
  85. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol. 2002;20:1499–1505
  86. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med. 2005;352:734–735
  87. Nelson R, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal metastases to the liver. Cochrane Database Sys Rev. 2004;4:CD003770
  88. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24:1395–1403
  89. Zelek L, Bugat R, Cherqui D. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol. 2003;14:1537–1542
  90. Kemeny N, Jarnigan W, Paty P. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23:4888–4899
  91. McCarty TM, Kuhn JA. Cryotherapy for liver tumors. Oncology (Huntingt). 1998;12:979–987
  92. Sotsky TK, Ravikumar TS. Cryotherapy in the treatment of liver metastases from colorectal cancer. Semin Oncol. 2002;29:183–191
  93. Cooper IS. Cryogenic surgery. N Engl J Med. 1963;268:743–749
  94. Ravikumar TS, Kane R, Cady B, et al. Hepatic cryosurgery with intraoperative ultrasound monitoring for metastatic colon carcinoma. Arch Surg. 1987;122:403–409
  95. Seifert JK, Morris DL. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. Ann Surg. 1998;228:201–208
  96. Weaver ML, Ashton JG, Zemel R. Treatment of colorectal liver metastases by cryotherapy. Semin Surg Oncol. 1998;14:163–170
  97. Wallace JR, Christians KK, Pitt HA, Quebbeman EJ. Cryotherapy extends the indications for treatment of colorectal liver metastases. Surgery. 1999;126:766–772
  98. Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer. 1995;76:501–509
  99. Bilchik AJ, Sarantou T, Foshag LJ, et al. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery. 1997;122:1040–1047
  100. McGahan JP, Browning PD, Brock JM, Tesluk H. Hepatic ablation using radiofrequency electrocautery. Invest Radiol. 1990;25:267–270
  101. Rossi S, Fornari F, Pathies C, Buscarini L. Thermal lesions induced by 480 KHz localized current field in guinea pig and pig liver. Tumori. 1990;76:54–57
  102. Goldberg SN, Gazelle GS, Compton CC, et al. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer. 2000;88:2452–2463
  103. Lencioni R, Cioni D, Bartolozzi C. Percutaneous radiofrequency thermal ablation of liver malignancies: techniques, indications, imaging findings, and clinical results. Abdom Imaging. 2001;26:345–360
  104. Scaife CL, Curley SA. Complication, local recurrence, and survival rates after radiofrequency ablation for hepatic malignancies. Surg Oncol Clin N Am. 2003;12:243–255
  105. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 1999;230:1–8
  106. Siperstein A, Garland A, Engle K, et al. Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol. 2000;7:106–113
  107. Wood TF, Rose DM, Chung M, et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol. 2000;7:593–600
  108. Iannitti DA, Dupuy DE, Mayo-Smith WW, Murphy B. Hepatic radiofrequency ablation. Arch Surg. 2002;137:422–426
  109. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005;23:1358–1364
  110. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26:985–990
  111. Vlastos G, Smith DL, Singletary SE, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol. 2004;11:869–874

PII: S0093-7754(07)00273-4

doi: 10.1053/j.seminoncol.2007.12.004

Seminars in Oncology
Volume 35, Issue 2 , Pages 147-159 , April 2008

Article Tools